{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:32Z","timestamp":1777277012111,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024LCYXZX01"],"award-info":[{"award-number":["2024LCYXZX01"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-026-07778-6","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:59:15Z","timestamp":1770598755000},"page":"3598-3606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Zijuan","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangqing","family":"Jiangchu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"7778_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2967\/jnumed.123.267006","volume":"65","author":"P Viscuse","year":"2024","unstructured":"Viscuse P, Devitt M, Dreicer R. Clinical management of advanced prostate cancer: where does radiopharmaceutical therapy fit in the treatment algorithm? J Nucl Med. 2024;65:679\u201385.","journal-title":"J Nucl Med"},{"key":"7778_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/pros.24056","volume":"80","author":"AK Miyahira","year":"2020","unstructured":"Miyahira AK, Pienta KJ, Babich JW, et al. Meeting report from the prostate cancer foundation PSMA theranostics state of the science meeting. Prostate. 2020;80:1273\u201396.","journal-title":"Prostate"},{"key":"7778_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate Cancer. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2017;58:1545\u201352.","journal-title":"Soc Nuclear Med"},{"issue":"suppl 3","key":"7778_CR4","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich J, Kratochwil C, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57(suppl 3):S79\u201389. .5.","journal-title":"J Nucl Med"},{"key":"7778_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bju.15143","volume":"126","author":"N Mayor","year":"2020","unstructured":"Mayor N, Sathianathen NJ, Buteau J, et al. Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU Int. 2020;126:525\u201335.","journal-title":"BJU Int"},{"key":"7778_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London England). 2021;397:797\u2013804.","journal-title":"Lancet (London England)"},{"issue":"9","key":"7778_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, et al. FDA approval summary: lutetium Lu 177 Vipivotide tetraxetan for patients with metastatic Castration-Resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651\u20137.","journal-title":"Clin Cancer Res"},{"key":"7778_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet (London England). 2024;404:1227\u201339.","journal-title":"Lancet (London England)"},{"key":"7778_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7778_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","volume":"43","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a metaanalysis. Clin Nucl Med. 2018;43:728\u201334.","journal-title":"Clin Nucl Med"},{"key":"7778_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","volume":"45","author":"I Virgolini","year":"2018","unstructured":"Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7778_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/imt.14.16","volume":"6","author":"C Seidl","year":"2014","unstructured":"Seidl C. Radioimmunotherapy with a-particle-emitting radionuclides. Immunotherapy. 2014;6:431\u201358.","journal-title":"Immunotherapy"},{"key":"7778_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11:200\u20138.","journal-title":"Curr Radiopharm"},{"key":"7778_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alphatherapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624\u201331.","journal-title":"J Nucl Med"},{"key":"7778_CR15","doi-asserted-by":"publisher","first-page":"796657","DOI":"10.3389\/fonc.2022.796657","volume":"12","author":"J Ma","year":"2022","unstructured":"Ma J, Li L, Liao T, et al. Efficacy and safety of (225)Ac-PSMA-617-Targeted alpha therapy in metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis. Front Oncol. 2022;12:796657.","journal-title":"Front Oncol"},{"key":"7778_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation therapy of metastatic Castration-Resistant prostate Cancer. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2016;57:1941\u20134.","journal-title":"Soc Nuclear Med"},{"key":"7778_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for Castration-Resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7778_CR18","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.7150\/thno.39838","volume":"10","author":"EM Velez","year":"2020","unstructured":"Velez EM, Desai B, Ji L, et al. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics. 2020;10:3254\u201362.","journal-title":"Theranostics"},{"key":"7778_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL, Practical PERCIST. A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576\u201384.","journal-title":"Radiology"},{"key":"7778_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas dermo-sifiliograficas. 2021;112:90\u20132.","journal-title":"Actas dermo-sifiliograficas"},{"key":"7778_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of overall and Disease-Free survival in metastatic Castration-Resistant prostate cancer patients receiving (225)Ac-PSMA-617 radioligand Therapy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2020;61:62\u20139.","journal-title":"Soc Nuclear Med"},{"key":"7778_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic Castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350.","journal-title":"Eur Urol"},{"key":"7778_CR23","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2967\/jnumed.123.265546","volume":"64","author":"N Alan-Selcuk","year":"2023","unstructured":"Alan-Selcuk N, Beydagi G, Demirci E, et al. Clinical experience with [225Ac]Ac-PSMA treatment in patients with [177Lu]Lu-PSMA\u2013Refractory metastatic Castration-Resistant prostate cancer. J Nucl Med. 2023;64:1574\u201380.","journal-title":"J Nucl Med"},{"key":"7778_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted \u03b1-Therapy of metastatic Castration-Resistant prostate cancer with (225)Ac-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor Control. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2018;59:795\u2013802.","journal-title":"Soc Nuclear Med"},{"issue":"33","key":"7778_CR25","doi-asserted-by":"publisher","first-page":"55094","DOI":"10.18632\/oncotarget.19049","volume":"8","author":"FC Gaertner","year":"2017","unstructured":"Gaertner FC, Halabi K, Ahmadzadehfar H, et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget. 2017;8(33):55094\u2013103.","journal-title":"Oncotarget"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07778-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07778-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:25:59Z","timestamp":1777274759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07778-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7778"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07778-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Southwest Medical University. Clinical trial number: AHSWMU-2020-035.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consents were obtained from the included subjects for participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that all human participants involved in this study have signed the consent form and agreed to the publication of their medical imaging.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}